癌症生物学与医学（英文版）2026，Vol.23Issue(8)：1051-1056,6.DOI:10.20892/j.issn.2095-3941.2026.0139
Less is more:patients with cervical cancer benefit from de-escalated chemotherapy plus immuno-targeted therapies
Less is more:patients with cervical cancer benefit from de-escalated chemotherapy plus immuno-targeted therapies
Bohao Zheng 1Dian Fan 2Shengtao Zhou2
作者信息
- 1. Department of Obstetrics and Gynecology,Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy,West China Second Hospital,Sichuan University and Collaborative Innovation Center,Chengdu 610000,China||Wuxi School of Medicine,Jiangnan University,Wuxi 214000,China
- 2. Department of Obstetrics and Gynecology,Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy,West China Second Hospital,Sichuan University and Collaborative Innovation Center,Chengdu 610000,China
- 折叠
引用本文复制引用
Bohao Zheng,Dian Fan,Shengtao Zhou..Less is more:patients with cervical cancer benefit from de-escalated chemotherapy plus immuno-targeted therapies[J].癌症生物学与医学（英文版）,2026,23(8):1051-1056,6.
